Skip to main content

Table 5 PharMetrics Database: Lung NET Prevalence, Cases per Million per Yeara

From: Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database

 

No. Of Cases Per Million Per Year (Numerator/Denominator)

2009

2010

2011

2012

2013

2014

Gender

Age

                  

 Female

18–24

2.9

(4

/1,388,059)

2.3

(3

/1,318,141)

3.5

(5

/1,431,236)

4.4

(6

/1,360,555)

2.2

(3

/1,335,252)

1.9

(2

/1,048,351)

25–34

6.6

(13

/1,960,213)

3.8

(7

/1,849,997)

8.1

(15

/1,851,913)

4.7

(8

/1,708,390)

7.1

(12

/1,684,490)

3.7

(5

/1,341,604)

35–44

6.0

(15

/2,508,808)

10.7

(25

/2,335,199)

6.6

(15

/2,269,096)

12.2

(25

/2,055,088)

20.3

(40

/1,969,715)

16.1

(25

/1,553,850)

45–54

18.7

(59

/3,149,529)

24.0

(71

/2,959,455)

26.5

(76

/2,867,408)

31.9

(82

/2,574,529)

32.8

(80

/2,436,504)

35.2

(66

/1,875,797)

55–64

38.2

(101

/2,643,692)

55.5

(143

/2,576,843)

65.6

(169

/2,575,456)

77.4

(184

/2,377,377)

92.0

(212

/2,305,347)

91.9

(165

/1,796,085)

All Femaleb

16.5

(192

/11,650,301)

22.6

(249

/11,039,635)

25.5

(280

/10,995,109)

30.3

(305

/10,075,939)

35.7

(347

/9,731,308)

34.5

(263

/7,615,687)

 Male

18–24

1.4

(2

/1,387,054)

1.5

(2

/1,322,440)

1.4

(2

/1,462,310)

2.8

(4

/1,406,293)

2.9

(4

/1,386,541)

3.6

(4

/1,097,662)

25–34

4.5

(8

/1,759,919)

3.0

(5

/1,671,459)

3.0

(5

/1,687,428)

1.9

(3

/1,609,181)

6.2

(10

/1,604,977)

2.3

(3

/1,323,432)

35–44

4.3

(10

/2,300,612)

12.6

(27

/2,147,076)

10.5

(22

/2,093,812)

9.3

(18

/1,928,820)

10.2

(19

/1,864,293)

10.6

(16

/1,505,314)

45–54

11.2

(32

/2,850,321)

14.9

(40

/2,681,967)

16.1

(42

/2,602,786)

20.2

(48

/2,375,529)

19.4

(44

/2,267,225)

17.9

(32

/1,786,707)

55–64

25.1

(60

/2,392,616)

33.5

(78

/2,331,410)

37.4

(87

/2,325,581)

33.8

(73

/2,158,306)

39.3

(83

/2,110,883)

44.5

(75

/1,684,375)

All Malec

10.5

(112

/10,690,522)

15.0

(152

/10,154,352)

15.5

(158

/10,171,917)

15.4

(146

/9,478,129)

17.3

(160

/9,233,919)

17.6

(130

/7,397,490)

 All Gender

18–24

2.2

(6

/2,775,113)

1.9

(5

/2,640,581)

2.4

(7

/2,893,546)

3.6

(10

/2,766,848)

2.6

(7

/2,721,793)

2.8

(6

/2,146,013)

25–34

5.6

(21

/3,720,132)

3.4

(12

/3,521,456)

5.7

(20

/3,539,341)

3.3

(11

/3,317,571)

6.7

(22

/3,289,467)

3.0

(8

/2,665,036)

35–44

5.2

(25

/4,809,420)

11.6

(52

/4,482,275)

8.5

(37

/4,362,908)

10.8

(43

/3,983,908)

15.4

(59

/3,834,008)

13.4

(41

/3,059,164)

45–54

15.2

(91

/5,999,850)

19.7

(111

/5,641,422)

21.6

(118

/5,470,194)

26.3

(130

/4,950,058)

26.4

(124

/4,703,729)

26.8

(98

/3,662,504)

55–64

32.0

(161

/5,036,308)

45.0

(221

/4,908,253)

52.2

(256

/4,901,037)

56.7

(257

/4,535,683)

66.8

(295

/4,416,230)

69.0

(240

/3,480,460)

All Patientsd

13.6

(304

/22,340,823)

18.9

(401

/21,193,987)

20.7

(438

/21,167,026)

23.1

(451

/19,554,068)

26.7

(507

/18,965,227)

26.2

(393

/15,013,177)

 

Adjusted Rate (No. Of Cases Per Million Per Year)b

All Femalec

16.2

21.8

24.8

29.5

34.9

34.0

All Maled

10.2

14.4

15.1

15.1

17.0

17.3

All Patientse

13.3

18.2

20.1

22.6

26.3

25.9

  1. a Cases of adults with ≥1 inpatient or ≥ 2 outpatient claims for Lung NET in listed year and continuous enrollment in year listed ÷ number of members with continuous enrollment in same period
  2. bAPC (95% CI; P value): female 16.3% (9.6–23.5; 0.002); male 9.5% (2.3–17.2; 0.021); all patients: 13.9% (7.4–20.9; 0.004)
  3. cAdjusted based on distribution of age among males from both databases in 2014
  4. dAdjusted based on distribution of age among females from both databases in 2014
  5. eAdjusted based on combined distribution of age among males from both databases in 2014
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us